# Quanterix Corp: overview

QTRX · Nasdaq · CIK 1503274 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qtrx.md) · [Financials](/companies/qtrx/financials.md) · [Filings](/companies/qtrx/filings.md) · [Insiders](/companies/qtrx/insiders.md)

Latest reported revenue: [$32.9m](/filings/0001503274-26-000036.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001503274-26-000036).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.8](/filings/0001503274-25-000106.md) | [35.2 d](/filings/0001503274-26-000013.md) | [30.3](/filings/0001503274-26-000021.md) | [24.5](/filings/0001503274-26-000036.md) | [40.2](/filings/0001503274-25-000106.md) | [43.9 d](/filings/0001503274-26-000013.md) | [36.4](/filings/0001503274-26-000021.md) | [32.9](/filings/0001503274-26-000036.md) |
| Gross margin | % | [56.3%](/filings/0001503274-25-000106.md) | [63.0% d](/filings/0001503274-26-000013.md) | [48.9%](/filings/0001503274-26-000021.md) | [40.9%](/filings/0001503274-26-000036.md) | [42.8%](/filings/0001503274-25-000106.md) | [45.7% d](/filings/0001503274-26-000013.md) | [42.7%](/filings/0001503274-26-000021.md) | [38.5%](/filings/0001503274-26-000036.md) |
| Operating margin | % | [(32.8%)](/filings/0001503274-25-000106.md) | [(42.0%) d](/filings/0001503274-26-000013.md) | [(86.9%)](/filings/0001503274-26-000021.md) | [(151.6%)](/filings/0001503274-26-000036.md) | [(92.8%)](/filings/0001503274-25-000106.md) | [(56.4%) d](/filings/0001503274-26-000013.md) | [(113.6%)](/filings/0001503274-26-000021.md) | [(150.2%)](/filings/0001503274-26-000036.md) |
| Net margin | % | [(23.3%)](/filings/0001503274-25-000106.md) | [(33.1%) d](/filings/0001503274-26-000013.md) | [(67.6%)](/filings/0001503274-26-000036.md) | [(122.6%)](/filings/0001503274-26-000036.md) | [(83.3%)](/filings/0001503274-25-000106.md) | [(52.7%) d](/filings/0001503274-26-000013.md) | [(48.2%)](/filings/0001503274-26-000036.md) | [(148.7%)](/filings/0001503274-26-000036.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001503274-25-000106.md) | not reported | [(0.53)](/filings/0001503274-26-000021.md) | [(0.77)](/filings/0001503274-26-000036.md) | [(0.73)](/filings/0001503274-25-000106.md) | not reported | [(0.37)](/filings/0001503274-26-000021.md) | [(1.04)](/filings/0001503274-26-000036.md) |
| Free cash flow | $m | [(6.6) d](/filings/0001503274-25-000106.md) | [(4.7) d](/filings/0001503274-26-000013.md) | [(15.1)](/filings/0001503274-26-000021.md) | [(6.4) d](/filings/0001503274-26-000036.md) | [(41.9) d](/filings/0001503274-25-000106.md) | [(16.5) d](/filings/0001503274-26-000013.md) | [(18.2)](/filings/0001503274-26-000021.md) | [(5.2) d](/filings/0001503274-26-000036.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [111](/filings/0001503274-24-000025.md) | [106](/filings/0001503274-25-000031.md) | [122](/filings/0001503274-26-000013.md) | [137](/filings/0001503274-26-000013.md) | [139](/filings/0001503274-26-000013.md) |
| Gross margin | % | [58.6%](/filings/0001503274-24-000025.md) | [43.0%](/filings/0001503274-25-000031.md) | [60.7%](/filings/0001503274-26-000013.md) | [60.5%](/filings/0001503274-26-000013.md) | [46.8%](/filings/0001503274-26-000013.md) |
| Operating margin | % | [(51.1%)](/filings/0001503274-24-000025.md) | [(98.8%)](/filings/0001503274-25-000031.md) | [(37.6%)](/filings/0001503274-26-000013.md) | [(38.3%)](/filings/0001503274-26-000013.md) | [(90.4%)](/filings/0001503274-26-000013.md) |
| Net margin | % | [(50.2%)](/filings/0001503274-24-000025.md) | [(94.4%)](/filings/0001503274-25-000031.md) | [(23.2%)](/filings/0001503274-26-000013.md) | [(28.0%)](/filings/0001503274-26-000013.md) | [(77.1%)](/filings/0001503274-26-000013.md) |
| Diluted EPS | $ per share | [(1.54)](/filings/0001503274-24-000025.md) | [(2.69)](/filings/0001503274-25-000031.md) | [(0.75)](/filings/0001503274-26-000013.md) | [(1.00)](/filings/0001503274-26-000013.md) | [(2.51)](/filings/0001503274-26-000013.md) |
| Free cash flow | $m | [(61.3)](/filings/0001503274-24-000025.md) | [(60.2)](/filings/0001503274-25-000031.md) | [(22.7)](/filings/0001503274-26-000013.md) | [(38.5)](/filings/0001503274-26-000013.md) | [(79.8)](/filings/0001503274-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/qtrx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.7m | 3,635,411 |  | Added +357,816 |
| [Blue Water Life Science Advisors, LP](/funds/1789778.md) | 2026-06-30 | $15.0m | 3,474,202 |  | Added +1,332,055 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $11.9m | 2,753,165 |  | Added +1,453,078 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $11.9m | 2,753,165 |  | Added +1,453,078 |
| [Portolan Capital Management, LLC](/funds/1350290.md) | 2026-06-30 | $8.2m | 1,899,308 |  | Reduced −1,046,515 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.8m | 1,800,644 |  | Added +16,031 |
| [Lionhunter Capital Management, LLC](/funds/2137268.md) | 2026-06-30 | $6.5m | 1,500,427 |  | Not compared |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $5.8m | 1,343,005 |  | Added +1,258,873 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.9m | 1,131,377 |  | Added +136,613 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $4.3m | 987,424 |  | Reduced −2,554,950 |

## Recent filings

[All 1,072 filings](/companies/qtrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-10 | 12:34 ET | [10-Q](/filings/0001503274-26-000036.md) | Quarterly report, period 2026-06-30 | 0001503274-26-000036 |
| 2026-08-10 | 12:07 ET | [8-K](/filings/0001503274-26-000035.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001503274-26-000035 |
| 2026-06-10 | 20:16 ET | [8-K](/filings/0001503274-26-000028.md) | 5.07 Shareholder vote results | 0001503274-26-000028 |
| 2026-06-09 | 12:06 ET | [8-K](/filings/0001628280-26-041773.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-041773 |
| 2026-05-26 | 21:25 ET | [8-K](/filings/0001503274-26-000024.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001503274-26-000024 |
| 2026-05-12 | 20:17 ET | [8-K](/filings/0001628280-26-034124.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-034124 |
| 2026-05-06 | 20:38 ET | [10-Q](/filings/0001503274-26-000021.md) | Quarterly report, period 2026-03-31 | 0001503274-26-000021 |
| 2026-05-06 | 20:07 ET | [8-K](/filings/0001503274-26-000019.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001503274-26-000019 |
| 2026-04-24 | 12:10 ET | [DEF 14A](/filings/0001104659-26-048166.md) | Proxy statement, period 2026-06-09 | 0001104659-26-048166 |
| 2026-03-02 | 21:35 ET | [10-K](/filings/0001503274-26-000013.md) | Annual report, period 2025-12-31 | 0001503274-26-000013 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001503274-26-000013.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/44399d5b-d87e-45bd-b6e5-b4f6da9c84d6)

## About the filer

- CIK: 1503274
- Tickers: QTRX
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.